Stockhub

Xenon Pharmaceuticals Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

21 August 2022

14 August 2022

10 August 2022

  • curprev 01:4201:42, 10 August 2022‎ 109.180.50.163 talk‎ 1,216 bytes +1,216‎ Created page with "Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neur..." Tag: Visual edit
Retrieved from ‘https://stockhub.co/research/Xenon_Pharmaceuticals_Inc.’